PERTH, Australia – After meeting with the FDA, Medlab Clinical Ltd. is reformulating its cannabinoid pain product into a synthetic formulation because the agency indicated it was more likely to register a synthetic compared to a botanic.
Brii Biosciences Ltd. shared interim data from a phase III trial of its neutralizing monoclonal antibody (mAb) combination therapy for SARS-CoV-2, BRII-196 and BRII-198, that showed a 78% reduction in the risk of hospitalization or death in patients receiving single dose of the cocktail.
Tracon Pharmaceuticals Inc. tapped Biocytogen Pharmaceuticals Co. Ltd.’s wholly owned subsidiary, Eucure Biopharma Co. Ltd., for U.S. rights to CTLA4 antibody YH-001, which it plans to use in immunotherapy studies in combination with its PD-L1 inhibitor.
Data presented at the American Association for Cancer Research virtual International Conference on Molecular Targets and Cancer Therapeutics, including Hummingbird Bioscience.
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Astrazeneca, Beigene, Biontech, Celltrion, Cocrystal, Daiichi Sankyo, Himalaya, Intellia, Janssen-Cilag, Johnson & Johnson, Moderna, Pfizer, RDIF, Takeda.
Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: Aditxt, Aipharma Global Holdings, Biontech, Curative, Debiopharm, Dexa Medica, Dr. Falk, Elixirgen, Glaxosmithkline, Hyloris, Janssen-Cilag International, Johnson & Johnson, Lumen, Merck, Mid-Atlantic, Nanoviricides, Neurorx, Pfizer, Relief, Renexxion Ireland, Sandoz, Therapeutic Solutions International, Vaxart.
Poseida Therapeutics Inc.’s R&D Day in February – where much of its technology was made public for the first time – created “a flood of interest” in deals and officials were “pretty selective,” said CEO Eric Ostertag, whose remarks came as the company nailed down a whopping research collaboration and exclusive license agreement with Takeda Pharmaceutical Co. Ltd. The arrangement will deploy Poseida’s Piggybac and Cas-CLOVER, as well as biodegradable DNA and RNA nanoparticle delivery technology and other genetic engineering platforms to come up with as many as eight gene therapies.
RSS
